PRFX's Business Model
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
| Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
| Website | https://www.painreform.com |
| CEO (Chief Executive Officer) | Ehud Geller |
| Number of Employees | |
| IPO date | September 1, 2020 |
PRFX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | IL |
| Address | 65 Yigal Alon Street |
| City | Tel Aviv |
| State | None |
| Phone | 972 3 717 7050 |
| Zip Code | 6745442 |
| Other Identifiers | |
| CIK | 0001801834 |
| ISIN | IL0011651580 |
| CUSIP | M77798102 |
| Open | 1.36 |
| Previous Close | 1.39 |
| Volume | 89.89 Thou. |
| Average Volume | 242 Thou. |
| Day’s Range | 1.36 – 1.425 |
| 52 Week Range | 0.432-16.63 |
| MA (50) | 1.81716 |
| MA (200) | 2.19529 |
| Market Cap | 2.82 Mil. |
| Shares Out. | 2.01 Mil. |
| Earnings Date | Aug 13, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
